Literature DB >> 21946845

Chemotherapy: advanced NSCLC--should we use doublets in elderly patients?

Robert Pirker1.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21946845     DOI： 10.1038/nrclinonc.2011.147

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

Review 1.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

Authors:  David G Pfister; David H Johnson; Christopher G Azzoli; William Sause; Thomas J Smith; Sherman Baker; Jemi Olak; Diane Stover; John R Strawn; Andrew T Turrisi; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2003-12-22       Impact factor: 44.544

2.  Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.

Authors:  Elisabeth Quoix; Gérard Zalcman; Jean-Philippe Oster; Virginie Westeel; Eric Pichon; Armelle Lavolé; Jérôme Dauba; Didier Debieuvre; Pierre-Jean Souquet; Laurence Bigay-Game; Eric Dansin; Michel Poudenx; Olivier Molinier; Fabien Vaylet; Denis Moro-Sibilot; Dominique Herman; Jaafar Bennouna; Jean Tredaniel; Alain Ducoloné; Marie-Paule Lebitasy; Laurence Baudrin; Silvy Laporte; Bernard Milleron
Journal:  Lancet       Date:  2011-08-08       Impact factor: 79.321

3.  Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-01-06       Impact factor: 13.506

4.  Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature.

Authors:  Giannicola D'Addario; Melania Pintilie; Natasha B Leighl; Ronald Feld; Thomas Cerny; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2005-02-22       Impact factor: 44.544

5.  Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer.

Authors:  G Frasci; V Lorusso; N Panza; P Comella; G Nicolella; A Bianco; G De Cataldis; A Iannelli; D Bilancia; M Belli; B Massidda; F Piantedosi; G Comella; M De Lena
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

6.  Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.

Authors:  Cesare Gridelli; Francesco Perrone; Ciro Gallo; Silvio Cigolari; Antonio Rossi; Francovito Piantedosi; Santi Barbera; Francesco Ferraù; Elena Piazza; Francesco Rosetti; Maurizia Clerici; Oscar Bertetto; Sergio Federico Robbiati; Luciano Frontini; Cosimo Sacco; Federico Castiglione; Adolfo Favaretto; Silvia Novello; Maria Rita Migliorino; Giampietro Gasparini; Domenico Galetta; Rosario Vincenzo Iaffaioli; Vittorio Gebbia
Journal:  J Natl Cancer Inst       Date:  2003-03-05       Impact factor: 13.506

7.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

8.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

9.  Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis.

Authors:  Catherine Delbaldo; Stefan Michiels; Nathalie Syz; Jean-Charles Soria; Thierry Le Chevalier; Jean-Pierre Pignon
Journal:  JAMA       Date:  2004-07-28       Impact factor: 56.272

10.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Authors:  Robert Pirker; Jose R Pereira; Aleksandra Szczesna; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Ihor Vynnychenko; Keunchil Park; Chih-Teng Yu; Valentyn Ganul; Jae-Kyung Roh; Emilio Bajetta; Kenneth O'Byrne; Filippo de Marinis; Wilfried Eberhardt; Thomas Goddemeier; Michael Emig; Ulrich Gatzemeier
Journal:  Lancet       Date:  2009-05-02       Impact factor: 79.321
  10 in total
  2 in total

Review 1.  Cetuximab in non-small-cell lung cancer.

Authors:  Robert Pirker; Martin Filipits
Journal:  Transl Lung Cancer Res       Date:  2012-03

2.  From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer.

Authors:  Robert Pirker; Martin Filipits
Journal:  ESMO Open       Date:  2019-09-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.